Related Experiment Video

Updated: Aug 2, 2025

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
13:14

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

10.5K

Generation of Rat Monoclonal Antibodies Against Human Epidermal Growth Factor Receptor 2

Honoka Yamamoto1, Takeshi Nakanishi1,2, Kan-Ichiro Ihara1,2

  • 1Department of Applied Chemistry and Bioengineering, Graduate School of Engineering, Osaka City University, Osaka-shi, Japan.

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
|April 19, 2023
PubMed

Insights

Researchers generated rat monoclonal antibodies (mAbs) targeting the human epidermal growth factor receptor 2 (HER2) extracellular domain. These antibodies successfully detected HER2 in HER2-expressing breast cancer cells, aiding HER2-targeted cancer therapy development.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Human epidermal growth factor receptor 2 (HER2) is a proto-oncogenic protein overexpressed in several cancers, including breast cancer.
  • HER2 signaling promotes cancer cell proliferation and inhibits apoptosis, making it a key target for tumor therapy.
  • Existing HER2-targeted therapies, like trastuzumab and pertuzumab, are monoclonal antibodies (mAbs) targeting HER2's extracellular domain (ECD).

Purpose of the Study:

  • To generate novel rat monoclonal antibodies (mAbs) against the extracellular domain (ECD) of human HER2.
  • To validate the efficacy of these generated mAbs in detecting HER2 in a relevant cancer cell line.

Main Methods:

  • Generation of rat monoclonal antibodies (mAbs) specifically against the human HER2 ECD.
  • Utilizing the HER2-expressing human breast cancer cell line SK-BR-3 for immunofluorescence staining.
  • Assessing the ability of the generated mAbs to detect intact and endogenous HER2.

Main Results:

  • Successfully generated rat monoclonal antibodies (mAbs) targeting the human HER2 extracellular domain (ECD).
  • Demonstrated that these mAbs can effectively detect both intact and endogenous HER2.
  • Confirmed HER2 detection in the SK-BR-3 human breast cancer cell line via immunofluorescence staining.

Conclusions:

  • The study successfully produced rat mAbs against the HER2 ECD.
  • These mAbs show potential for detecting HER2 in cancer cells, supporting further development for HER2-targeted cancer diagnostics and therapeutics.
Keywords:
HER2cancermonoclonal antibody

More Related Videos

Generation of Murine Monoclonal Antibodies by Hybridoma Technology09:42

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

42.0K
Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

18.5K

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K